{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:48:12Z","timestamp":1782805692670,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>IDH-mutant glioma management has been rapidly evolving following the 2024 FDA approval of the mutant IDH inhibitor (IDHi), vorasidenib. However, optimal treatment decisions for many specific scenarios remain unclear. The aim of this study was to provide insight into how clinicians collectively approach different clinical scenarios and evaluate how demographic and professional backgrounds influence decision-making for IDH-mutant glioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A survey was developed by a team of neuro-oncologists and radiation oncologists and distributed via email and X (formerly Twitter) to clinicians who treat patients with IDH-mutant glioma (neuro\/medical oncologists, radiation oncologists, and neurosurgeons). The survey included demographic questions and 10\u201313 case-based clinical scenarios with standardized response options. We compared responses between neuro\/medical oncologists and radiation oncologists and performed univariable regression to identify predictors of treatment preference and IDHi familiarity\/enthusiasm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 153 clinicians (58% neuro\/medical-oncologists, 34% radiation oncologists, 8% neurosurgeons) completed the survey. Five of ten scenarios reached consensus (&gt;\u200975% agreement on a treatment option), while the remainder demonstrated heterogeneity. Compared to neuro\/medical oncologists, radiation oncologists were less likely to recommend IDHi (IRR 0.57,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and more likely to recommend radiotherapy (IRR 1.54,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) or chemoradiotherapy (IRR 1.47,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Neuro-oncologists and neurosurgeons reported the most and least familiarity with IDHi, respectively, whereas medical oncologists and radiation oncologists reported the most and least enthusiasm for IDHi, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Substantial variation exists in real-world management of IDH-mutant glioma across specialties and institutions. While several clinical scenarios demonstrated strong consensus, others revealed uncertainty, underscoring the need for ongoing multidisciplinary collaboration and further advances in evidence-based consensus to guide clinical decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05630-3","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:08:32Z","timestamp":1780906112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional survey"],"prefix":"10.1007","volume":"178","author":[{"given":"Tyler A.","family":"Lanman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7699-5188","authenticated-orcid":false,"given":"L. Nicolas","family":"Gonzalez Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley K.","family":"Perlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy E.","family":"Strowd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kushnirsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankush","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"5630_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/neuonc\/noac207","volume":"25","author":"JJ Miller","year":"2023","unstructured":"Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, Andronesi O, Barnholtz-Sloan JS, Baumert BG, Berger MS et al (2023) Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol 25:4\u201325","journal-title":"Neuro Oncol"},{"key":"5630_CR2","first-page":"CD013047","volume":"8","author":"TA Lawrie","year":"2019","unstructured":"Lawrie TA, Gillespie D, Dowswell T, Evans J, Erridge S, Vale L, Kernohan A, Grant R (2019) Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma. Cochrane Database Syst Rev 8:CD013047","journal-title":"Cochrane Database Syst Rev"},{"key":"5630_CR3","doi-asserted-by":"publisher","first-page":"e213797","DOI":"10.1212\/WNL.0000000000213797","volume":"105","author":"T Lanman","year":"2025","unstructured":"Lanman T, Densmore I, Nagpal S, Recht L, McGranahan T (2025) Characteristics and Outcomes of Patients With IDH-Mutant Grade 2 and 3 Gliomas After Deferred or Adjuvant Radiotherapy. Neurology 105:e213797","journal-title":"Neurology"},{"key":"5630_CR4","doi-asserted-by":"crossref","unstructured":"Soffietti R, Pellerino A, Bruno F, Mauro A, Ruda R (2023) Neurotoxicity from Old and New Radiation Treatments for Brain Tumors. Int J Mol Sci 24","DOI":"10.3390\/ijms241310669"},{"key":"5630_CR5","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231\u20131251","journal-title":"Neuro Oncol"},{"key":"5630_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP et al (2023) Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med 389:589\u2013601","journal-title":"N Engl J Med"},{"key":"5630_CR7","doi-asserted-by":"crossref","unstructured":"Lanman TA, Gonzalez Castro LN (2025) Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review. Cancers (Basel) 17","DOI":"10.3390\/cancers17162630"},{"key":"5630_CR8","first-page":"i6","volume":"12","author":"A Darlix","year":"2025","unstructured":"Darlix A, Preusser M, Hervey-Jumper SL, Shih HA, Mandonnet E, Taylor JW (2025) Who will benefit from vorasidenib? Review of data from the literature and open questions. Neurooncol Pract 12:i6\u2013i18","journal-title":"Neurooncol Pract"},{"key":"5630_CR9","first-page":"199","volume":"11","author":"KB Peters","year":"2024","unstructured":"Peters KB, Alford C, Heltemes A, Savelli A, Landi DB, Broadwater G, Desjardins A, Johnson MO, Low JT, Khasraw M et al (2024) Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma. Neurooncol Pract 11:199\u2013204","journal-title":"Neurooncol Pract"},{"key":"5630_CR10","first-page":"vdae227","volume":"7","author":"TA Lanman","year":"2025","unstructured":"Lanman TA, Youssef G, Huang R, Rahman R, DeSalvo M, Flood T, Hassanzadeh E, Lang M, Lauer J, Potter C et al (2025) Ivosidenib for the treatment of IDH1-mutant glioma, grades 2\u20134: Tolerability, predictors of response, and outcomes. Neurooncol Adv 7:vdae227","journal-title":"Neurooncol Adv"},{"key":"5630_CR11","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1158\/1078-0432.CCR-23-0585","volume":"29","author":"DO Kamson","year":"2023","unstructured":"Kamson DO, Puri S, Sang Y, Shi MJ, Blair L, Blakeley JO, Laterra J (2023) Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase-mutant Astrocytic and Oligodendroglial Tumors. Clin Cancer Res 29:4863\u20134869","journal-title":"Clin Cancer Res"},{"key":"5630_CR12","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","volume":"374","author":"JC Buckner","year":"2016","unstructured":"Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD et al (2016) Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med 374:1344\u20131355","journal-title":"N Engl J Med"},{"key":"5630_CR13","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1200\/JCO.19.02983","volume":"38","author":"EH Bell","year":"2020","unstructured":"Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ et al (2020) Comprehensive Genomic Analysis in NRG Oncology\/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. J Clin Oncol 38:3407\u20133417","journal-title":"J Clin Oncol"},{"key":"5630_CR14","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1200\/JCO.23.02195","volume":"42","author":"R Kotecha","year":"2024","unstructured":"Kotecha R, Schiff D, Chakravarti A, Fleming JL, Brown PD, Puduvalli VK, Vogelbaum MA, Gondi V, Gallus M, Okada H et al (2024) Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era. J Clin Oncol 42:2588\u20132598","journal-title":"J Clin Oncol"},{"key":"5630_CR15","doi-asserted-by":"publisher","first-page":"110640","DOI":"10.1016\/j.radonc.2024.110640","volume":"202","author":"MC Tom","year":"2025","unstructured":"Tom MC, Nagpal S, Palmer JD, Breen WG, Pollom EL, Lehrer EJ, McGranahan TM, Shiue K, Chundury A, McClelland Iii S et al (2025) An update to the American Radium Society\u2019s appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors. Radiother Oncol 202:110640","journal-title":"Radiother Oncol"},{"key":"5630_CR16","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1093\/neuonc\/noae107","volume":"26","author":"MJ van den Bent","year":"2024","unstructured":"van den Bent MJ, French PJ, Brat D, Tonn JC, Touat M, Ellingson BM, Young RJ, Pallud J, von Deimling A, Sahm F et al (2024) The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors? Neuro Oncol 26:1805\u20131822","journal-title":"Neuro Oncol"},{"key":"5630_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11060-024-04861-6","volume":"171","author":"M Ziu","year":"2025","unstructured":"Ziu M, Halasz LM, Kumthekar PU, McGranahan TM, Lo SS, Olson JJ (2025) Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of chemotherapy in newly diagnosed WHO Grade II diffuse glioma in adults: update. J Neurooncol 171:279\u2013298","journal-title":"J Neurooncol"},{"key":"5630_CR18","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1016\/j.ijrobp.2024.07.2290","volume":"120","author":"JL Fleming","year":"2024","unstructured":"Fleming JL, Iwamoto F, Polley MY, Shaw EG, Buckner J, Barger GR, Ricci PE, Gilbert M, Bullard DE, Brown PD et al (2024) Clinical Endpoints Correlation with Molecular Features in the NRG Oncology\/RTOG 9802 Low-Grade Glioma, Low-Risk Observation Arm. Int J Radiat Oncol Biol Phys 120:S214","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5630_CR19","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/neuonc\/noaf133","volume":"27","author":"AB Lasica","year":"2025","unstructured":"Lasica AB, Lan Z, Miller JJ, Jiao A, Pan I, Aker L, Prabhakar P, Japo J, Russ A, Westergaard C et al (2025) Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4. Neuro Oncol 27:2382\u20132398","journal-title":"Neuro Oncol"},{"key":"5630_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s11060-024-04852-7","volume":"171","author":"EA Wetzel","year":"2025","unstructured":"Wetzel EA, Nohman AI, Hsieh AL, Reuss D, Unterberg AW, Eyupoglu IY, Hua L, Youssef G, Wen PY, Cahill DP et al (2025) A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design. J Neurooncol 171:373\u2013381","journal-title":"J Neurooncol"},{"key":"5630_CR21","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","volume":"22","author":"MJ van den Bent","year":"2021","unstructured":"van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF et al (2021) Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053\u2009\u2013\u200922054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol 22:813\u2013823","journal-title":"Lancet Oncol"},{"key":"5630_CR22","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1200\/JCO.19.03327","volume":"38","author":"IK Mellinghoff","year":"2020","unstructured":"Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, Cote GM, Burris H, Janku F, Young RJ et al (2020) Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. J Clin Oncol 38:3398\u20133406","journal-title":"J Clin Oncol"},{"key":"5630_CR23","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-21-0611","volume":"27","author":"IK Mellinghoff","year":"2021","unstructured":"Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA 3rd, Maher EA, Janku F, Cote GM, de la Fuente MI, Clarke JL, Ellingson BM et al (2021) Vorasidenib, a Dual Inhibitor of Mutant IDH1\/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clin Cancer Res 27:4491\u20134499","journal-title":"Clin Cancer Res"},{"key":"5630_CR24","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/neuonc\/noac155","volume":"25","author":"A Natsume","year":"2023","unstructured":"Natsume A, Arakawa Y, Narita Y, Sugiyama K, Hata N, Muragaki Y, Shinojima N, Kumabe T, Saito R, Motomura K et al (2023) The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. Neuro Oncol 25:326\u2013336","journal-title":"Neuro Oncol"},{"key":"5630_CR25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/neuonc\/noac139","volume":"25","author":"MI de la Fuente","year":"2023","unstructured":"de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K et al (2023) Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib\/II trial. Neuro Oncol 25:146\u2013156","journal-title":"Neuro Oncol"},{"key":"5630_CR26","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1093\/neuonc\/noad113","volume":"25","author":"M Preusser","year":"2023","unstructured":"Preusser M, Geurts M, Hainfellner JA, van den Bent MJ (2023) What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib? Neuro Oncol 25:1915\u20131917","journal-title":"Neuro Oncol"},{"key":"5630_CR27","doi-asserted-by":"crossref","unstructured":"Lanman TA, Wetzel EA, Verma K, Gonzalez Castro LN (2025) Reproductive health considerations for IDH-mutant glioma patients considering IDH inhibitor therapy: A retrospective cohort study. Neuro-Oncology Practice","DOI":"10.1093\/nop\/npaf071"},{"key":"5630_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-018-2851-3","volume":"139","author":"A van Westrhenen","year":"2018","unstructured":"van Westrhenen A, Senders JT, Martin E, DiRisio AC, Broekman MLD (2018) Clinical challenges of glioma and pregnancy: a systematic review. J Neurooncol 139:1\u201311","journal-title":"J Neurooncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05630-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05630-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05630-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:34:05Z","timestamp":1782804845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05630-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5630"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05630-3","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"24 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study consisted of a voluntary survey of clinicians and did not include any patient data or personal health information. As such, it did not require review by an institutional review board. The investigation was conducted in accordance with the principles of the World Medical Association Declaration of Helsinki: Research Involving Human Participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Participants were informed of the purpose of the study, and completion of the survey was considered to indicate informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No personally identifiable material was included in this report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"L.N.G.C. has received honoraria from Elsevier, BMJ Best Practice, Oakstone Publishing, Prime Education and Servier, as well as research support from Merck & Co, Conquer Cancer (The ASCO Foundation), the Robert Wood Johnson Foundation, the Robert A. Winn Excellence in Clinical Trials Award Program, and the National Cancer Institute. H.K.P. reports consulting role: Novocure.R.E.S. reports grants or contract to his institution from the National Institutes of Health; personal royalites from Elsevier and Lecturio; consulting fees from Monteris Medical, Novocure, and SpringWorks Therapeutics; participation on a data safety monitoring board for tanezumab (Massachusetts General Hospital); editorial stipend from the American Academy of Neurology; and board membership of the Accreditation Council for Continuing Medical Education and the North Carolina Medical Society Foundation. M.T.M. reports honoraria; Wolters Kluwer. Section Editor; Int J Radiat Oncol Biol Phys. develop guidelines; American Radium Society.M.T.M. reports honoraria from Wolters Kluwer. Consulting\/Advisory Role: Nuvation Bio, Deciphera, Telix, Servier, Alexion Pharmaceuticals, Inc. P.Y.W. reports grants or contracts from AstraZeneca, Black Diamond, Bristol Myers Squibb, Chimerix, the Global Coalition for Adaptive Research, Kazia, MediciNova, Merck, Nerviano, Novartis, Philogen, Quadriga, and Servier; consulting fees from Alexion\/AstraZeneca, Bristol Myers Squibb, Chimerix, Day One Bio, ImVax, Fore Biotherapeutics, Genenta, GlaxoSmithKline, Merck, Nerviano, Nuvation Bio Medical Sciences, Novartis, Novocure, Rigel, Sapience, Servier, and Telix; payment or honoraria from Medscape, Med Learning, Peer Review CME, and Research to Practice.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}